Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6317697 | 0.91 | GABRA1 (0.47) | GABRA1LMNARAB9ATSHRACACB | |
| SCHEMBL6316368 | 0.91 | GABRA1 (0.46) | GABRA1LMNARAB9ATSHRACACB | |
| SCHEMBL6315386 | 0.90 | GABRA1 (0.49) | GABRA1LMNARAB9ATSHRACACB | |
| SCHEMBL6322798 | 0.89 | GABRA1 (0.49) | GABRA1LMNARAB9ATSHRACACB | |
| SCHEMBL6323390 | 0.88 | GABRA1 (0.50) | GABRA1LMNARAB9ATSHRACACB | |
| SCHEMBL6318899 | 0.87 | GABRA1 (0.49) | GABRA1LMNARAB9ATSHRACACB | |
| SCHEMBL6323876 | 0.86 | CNR1 (0.46) | GABRA1LMNAACACB | |
| SCHEMBL6316178 | 0.85 | GABRA1 (0.47) | GABRA1LMNARAB9ATSHRGABRA5 | |
| SCHEMBL6317173 | 0.84 | GABRA1 (0.49) | GABRA1LMNARAB9ATSHRGABRA5 | |
| SCHEMBL6316655 | 0.83 | GABRA1 (0.49) | GABRA1LMNARAB9ATSHRGABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197633-A1 | N-Alkyl-Heterocyclyl Carboxamide Derivatives | BAYER CROPSCIENCE S.A. (FR) | 2010-08-05 | — | — | US | claimed |
| EP-1937637-A1 | NEW N-ALKYL-HETEROCYCLYL CARBOXAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2008-07-02 | — | — | EP | claimed |
| WO-2007039615-A1 | NEW N-ALKYL-HETEROCYCLYL CARBOXAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2007-04-12 | — | — | WO | claimed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | claimed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | claimed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | claimed |
| US-8148538-B2 | N-alkyl-heterocyclyl carboxamide derivatives | BAYER CROPSCIENCE AG (DE) | 2012-04-03 | — | — | US | disclosed |
| US-20100197633-A1 | N-Alkyl-Heterocyclyl Carboxamide Derivatives | BAYER CROPSCIENCE S.A. (FR) | 2010-08-05 | — | — | US | disclosed |
| EP-1937637-A1 | NEW N-ALKYL-HETEROCYCLYL CARBOXAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039615-A1 | NEW N-ALKYL-HETEROCYCLYL CARBOXAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2007-04-12 | — | — | WO | disclosed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | disclosed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | GABRA1 886/4885LMNA 3334/4885RAB9A 1754/4885 |
| US-20100197633-A1 | N-Alkyl-Heterocyclyl Carboxamide Derivatives | CYP1A2, CYP3A7, GANC | GABRA1 485/4885LMNA 2548/4885RAB9A 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.